TY - JOUR
T1 - Phenotype, management and predictors of outcome in a large cohort of adult congenital heart disease patients with heart failure
AU - Van De Bruaene, Alexander
AU - Hickey, Edward J.
AU - Kovacs, Adrienne H.
AU - Crean, Andrew M.
AU - Wald, Rachel M.
AU - Silversides, Candice K.
AU - Redington, Andrew N.
AU - Ross, Heather J.
AU - Alba, Ana Carolina
AU - Billia, Filio
AU - Nair, Krishnakumar
AU - Benson, Lee
AU - Horlick, Eric
AU - Osten, Mark
AU - Colman, Jack
AU - Heggie, Jane
AU - Oechslin, Erwin N.
AU - Roche, S. Lucy
N1 - Funding Information:
Alexander Van De Bruaene is supported by a grant of the Frans van de Werf Fund for Clinical Cardiovascular Research and the Research Foundation Flanders (FWO). He is also the recipient of the Nevil Thomas Fellowship in Adult Congenital Heart Disease 2017.
Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Objective Although heart failure (HF) is the leading cause of premature death in adult congenital heart disease (ACHD), little population-specific data exist. This study reports early experience from a dedicated, sub-specialty adult congenital heart disease-heart failure (ACHD-HF) clinic, aiming to identify risk factors for adverse outcome. Methods Between 2012 and 2015, 126 patients (57% male) attended the ACHD-HF clinic. Baseline and follow-up data were analysed and compared across 4 anatomical/physiological subgroups: cyanotic ACHD, Fontan circulation (1V), biventricular circulation with a subaortic right ventricle (2V-RV) and biventricular circulation with a subaortic left ventricle (2V-LV). Predictors of the composite primary outcome: death, transplant or ventricular assist device (VAD) were identified using multivariable Cox proportional hazard models. Results Mean age at first visit was 38 ± 13 years. Patients were grouped as follows: cyanotic ACHD 10%, 1 V 24%, 2V-RV 29% and 2V-LV 37%. During a median follow-up of 1.7 (IQR 0.8–2.9) years, 38 patients (30%) reached the primary outcome. Event-free survival was 89%, 78% and 63% at 1, 2 and 3 years. Forty (31.7%) patients experienced 69 HF hospitalisations. Between-group differences were noted for systolic function, valvular regurgitation, pacing prevalence and invasive hemodynamics. Multivariable analysis revealed 2V-RV subgroup (p = 0.001), NYHA class (p = 0.002) B-type natriuretic peptide > 164 pg/ml (p = 0.003) and sodium < 136 mmol/L (p = 0.036) as independently associated with death, transplant or VAD. Conclusions Our young ACHD-HF patients experienced high adverse event rates during a short period of follow-up. The prognostic markers identified will aid clinicians to stratify short-term risk and thereby guide advanced HF management decisions in ACHD.
AB - Objective Although heart failure (HF) is the leading cause of premature death in adult congenital heart disease (ACHD), little population-specific data exist. This study reports early experience from a dedicated, sub-specialty adult congenital heart disease-heart failure (ACHD-HF) clinic, aiming to identify risk factors for adverse outcome. Methods Between 2012 and 2015, 126 patients (57% male) attended the ACHD-HF clinic. Baseline and follow-up data were analysed and compared across 4 anatomical/physiological subgroups: cyanotic ACHD, Fontan circulation (1V), biventricular circulation with a subaortic right ventricle (2V-RV) and biventricular circulation with a subaortic left ventricle (2V-LV). Predictors of the composite primary outcome: death, transplant or ventricular assist device (VAD) were identified using multivariable Cox proportional hazard models. Results Mean age at first visit was 38 ± 13 years. Patients were grouped as follows: cyanotic ACHD 10%, 1 V 24%, 2V-RV 29% and 2V-LV 37%. During a median follow-up of 1.7 (IQR 0.8–2.9) years, 38 patients (30%) reached the primary outcome. Event-free survival was 89%, 78% and 63% at 1, 2 and 3 years. Forty (31.7%) patients experienced 69 HF hospitalisations. Between-group differences were noted for systolic function, valvular regurgitation, pacing prevalence and invasive hemodynamics. Multivariable analysis revealed 2V-RV subgroup (p = 0.001), NYHA class (p = 0.002) B-type natriuretic peptide > 164 pg/ml (p = 0.003) and sodium < 136 mmol/L (p = 0.036) as independently associated with death, transplant or VAD. Conclusions Our young ACHD-HF patients experienced high adverse event rates during a short period of follow-up. The prognostic markers identified will aid clinicians to stratify short-term risk and thereby guide advanced HF management decisions in ACHD.
KW - Adult congenital heart disease
KW - B-type natriuretic peptide
KW - Heart failure
KW - Transplant
KW - Ventricular assist device
UR - http://www.scopus.com/inward/record.url?scp=85032882934&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032882934&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2017.10.086
DO - 10.1016/j.ijcard.2017.10.086
M3 - Article
C2 - 29103857
AN - SCOPUS:85032882934
SN - 0167-5273
VL - 252
SP - 80
EP - 87
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -